Boston musings.
P2B or P3 may be the burning question.
Pathways??
I wonder if the new HIV/225 patents will be part of a change of tack, with regard to the parameters of the next trial. Will they pursue eradication or will they pursue to prove the human value of the immune response over a longer period.
Is a treatment interruption trial, as mentioned previously by MM in an interview, no longer a pipedream here?
Will they take aim at both?
How?
Boston musings. P2B or P3 may be the burning question....
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.0¢ |
Change
-0.001(1.41%) |
Mkt cap ! $63.61M | |||
| Open | High | Low | Value | Volume |
| 7.1¢ | 7.3¢ | 7.0¢ | $54.87K | 775.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 516076 | 7.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.1¢ | 40636 | 2 |
View Market Depth
| Last trade - 14.58pm 19/04/2024 (20 minute delay) ? |
|
|||||
|
Last
7.0¢ |
Change
-0.001 ( 1.41 %) |
||||
| Open | High | Low | Volume | ||
| 7.1¢ | 7.1¢ | 7.0¢ | 212891 | ||
| Last updated 14.05pm 19/04/2024 ? | |||||
| BIT (ASX) Chart |